CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool
World Journal of Microbiology and Biotechnology · 2025
DOI: 10.1007/s11274-025-04591-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Microbiology and Biotechnology, 2025. Verfasst von Shuqi Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, P.R. China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Anti-Infective Agents. Die Arbeit nennt 164 Literaturangaben. Gefördert von: College Students' Innovation and Entrepreneurship Training Program of Shandong Second Medical University, Natural Science Foundation of Shandong Province, China, College Students’ Innovation and Entrepreneurship Training Program of Shandong Second Medical University.
Abstract (Originalsprache)
The emergence of antimicrobial resistance (AMR) and the slow pace of new antibiotic development have contributed to an increase in mortality from bacterial infections, posing a significant threat to human health worldwide. In light of this, there is an urgent need to develop novel antimicrobial agents to complement or replace antibiotics. Clustered regularly interspaced short palindromic repeats-CRISPR-associated protein (CRISPR-Cas) technology, with its powerful and efficient gene-editing capabilities, has emerged as a promising novel antimicrobial agent to combat AMR. CRISPR-Cas systems can be delivered into bacteria in a variety of ways, targeting specific genes and killing bacteria with high precision without affecting normal flora. Bacteriophages (or phages) are another promising antimicrobial agent due to their specific bactericidal effects. CRISPR-Cas technology can also be used to edit phage genomes and alter phage properties, including addressing the limitations of phage therapeutic applications such as expanding the host range and enhancing bactericidal properties. This paper summarizes the composition and mechanism of action of different CRISPR systems, vectors for delivery of CRISPR systems, and their advantages and limitations. It also provides an overview of recent progress in the application of CRISPR-Cas systems to combat antimicrobial resistance and enhance the bactericidal properties of phages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, P.R. China.
- Department of Basic Medicine, Weifang Nursing Vocational College, Weifang, 262500, Shandong, PR China.
- Department of Clinical Laboratory, Affiliated Hospital of Shandong Second Medical University, Weifang, 261031, Shandong, PR China.
- Department of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, P.R. China. qiaojj@sdsmu.edu.cn.
Förderung
- College Students' Innovation and Entrepreneurship Training Program of Shandong Second Medical University
- Natural Science Foundation of Shandong Province, China
- College Students’ Innovation and Entrepreneurship Training Program of Shandong Second Medical University
Zitieren
APA
Yang, S., Jiao, X., Liu, J., Liu, Y., Wang, M., Li, S., & Qiao, J. (2025). CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool. World Journal of Microbiology and Biotechnology. https://doi.org/10.1007/s11274-025-04591-5
Vancouver
Yang S, Jiao X, Liu J, Liu Y, Wang M, Li S, et al. CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool. World Journal of Microbiology and Biotechnology. 2025. doi:10.1007/s11274-025-04591-5
BibTeX
@article{Yang2025,
author = {Yang, Shuqi and Jiao, Xin and Liu, Jiayi and Liu, Yanxia and Wang, Menglu and Li, Sihan and Qiao, Jinjuan},
title = {CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool},
journal = {World Journal of Microbiology and Biotechnology},
year = {2025},
doi = {10.1007/s11274-025-04591-5}
}
EUVIMED